Author/Year |
Trial group interventions |
Trial group interventions |
Trial group interventions |
C: Interventions |
Main outcome indicators |
Secondary outcome indicators |
gauge |
|
Specific measures |
Frequency and Periodicity |
Systems/platforms |
|
|
|
|
Cao/202314
|
VR United Minds |
March |
VR Glasses
(Model MN391) |
routine care |
①② |
⑧⑫ |
T-DAS, EORTC
QLQC30, self-made
Satisfaction
Questionnaire
|
Shin MD/202315
|
Receive virtual reality-based
explanations of radiotherapy procedures in addition to standard
information |
7-8 min/session, 3 assessment time points |
Oculus Quest
Wireless Virtual Reality Headset |
Routine health education on
radiotherapy |
② |
⑪ |
APAIS, STAI and LASA |
Zhang/202216
|
VR-CALM, immersion in landscapes such
as the seaside and Butterfly Valley, where patients can walk around,
hear the wind and touch butterflies |
30min/trip, 6 times in total |
(Headgear and controller) |
routine care |
①②③ |
⑤⑥ |
FACT-B, DT, CARS,
PFS, PSQI, SAS, SDS |
Chirico/201918
|
Immersive and interactive virtual
reality |
For chemotherapy, ≥20 minutes |
Head-mounted glasses (Vuzix
Wrap 1200 VR) and head movement tracking system |
Music therapy/
conventional chemotherapy |
② ③ ⑤ |
⑩ |
SAI, SV- POMS,
VRSQ |
Mohammad/201819
|
drug + virtual reality sessions. |
15 min/dose at time of administration, 4 months |
Virtual environments,
distraction interventions |
drug analgesia |
② ④ |
(vii) |
VAS, SAI,
MMSE |
Reynolds/202217
|
Virtual environment ”Happy Place +
Ripples”, home intervention, measured at 6 different time points |
4
weeks, 6 assessment time points |
VR headset + headphones |
Virtual
environment ”Ripple + Happy Place”, home-based intervention |
① |
② ③ ④
⑤ ⑨ |
EQ-5D-5L, VAS, FACIT-Fatigue, BPI, DASS-SF |